sorbitol has been researched along with Diabetes Mellitus, Type 2 in 114 studies
D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to assess the effect of luseogliflozin on liver fat deposition and compare luseogliflozin to metformin in type 2 diabetes (T2D) patients with non-alcoholic fatty liver disease (NAFLD)." | 9.27 | Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. ( Fushimi, N; Hachiya, H; Ito, S; Kawai, H; Kawai, M; Mori, A; Ohashi, N; Shibuya, T; Yoshida, Y, 2018) |
| "To assess the therapeutic effect of losartan on type 2 diabetes mellitus (DM2) with gas chromatography (GC)-based metabonomics." | 7.74 | [Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics]. ( Gao, P; Lu, X; Shi, XZ; Xu, GW; Yuan, KL, 2007) |
| "This study aimed to assess the effect of luseogliflozin on liver fat deposition and compare luseogliflozin to metformin in type 2 diabetes (T2D) patients with non-alcoholic fatty liver disease (NAFLD)." | 5.27 | Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. ( Fushimi, N; Hachiya, H; Ito, S; Kawai, H; Kawai, M; Mori, A; Ohashi, N; Shibuya, T; Yoshida, Y, 2018) |
| " This study intends to examine the effects of sea buckthorn and metformin on body weight, water and feed intake, glycaemia, insulinemia, sorbitol accumulation and cataract development in Zucker diabetic fatty rats, which represent an animal model of type 2 Diabetes mellitus, as well as to characterize the individual content of bioactive substances and the antioxidant activity of sea buckthorn." | 4.12 | The consumption of sea buckthorn (Hippophae rhamnoides L.) effectively alleviates type 2 diabetes symptoms in spontaneous diabetic rats. ( Brindza, J; Capcarova, M; Dupak, R; Hrnkova, J; Ivanisova, E; Kalafova, A; Kovac, J; Prnova, MS; Schneidgenova, M; Simonova, N; Tokarova, K, 2022) |
| " This indicates the following metabolic derangements in DME: (a) a higher amount of oxidized fatty acids but a lower amount of endogenous antioxidants (oxidative stress); (b) higher levels of β-glucose and homocysteine but a lower level of sorbitol (hyperglycemia); (c) a higher amount of prostaglandin metabolites (inflammation); (d) higher amounts of acylcarnitines, odd-numbered fatty acids, and 7,8-diaminononanoate (respiration deterioration); (e) a higher amount of neurotransmitter metabolites and homovanillic acid (neuronal damage); (f) a lower amount of extracellular matrix (ECM) constituents (ECM deterioration); and (g) a higher amount of di-amino peptides (microvascular damage)." | 4.12 | Untargeted metabolomic analysis of aqueous humor in diabetic macular edema. ( Bakthavatsalam, M; Brelen, ME; Chan, KP; Chan, TI; Chu, KO; Pang, CP; Wang, CC; Yip, YW, 2022) |
| "Sodium-glucose co-transporter type 2 inhibitors (luseogliflozin 5 mg/day or canagliflozin 100 mg/day) reduced body weight, HbA1c, albuminuria, estimated glomerular filtration rate and office blood pressure." | 3.85 | Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy. ( Kishimoto, M; Ohta, M; Suzuki, H; Takenaka, T; Tomonaga, O, 2017) |
| "In this observational study, fasting glucose, sorbitol and fructose concentrations were measured using gas-chromatography-liquid mass spectroscopy in cerebrospinal fluid (CSF), maternal plasma, and venous cord blood collected from 25 pregnant women (6 lean, 10 overweight/obese, and 9 T2DM/gestational DM) undergoing spinal anesthesia and elective cesarean section." | 3.81 | Fructose levels are markedly elevated in cerebrospinal fluid compared to plasma in pregnant women. ( Belfort-DeAguiar, R; Cline, G; Han, CS; Hwang, JJ; Johnson, A; Khokhar, B; Sherwin, RS; Snegovskikh, D, 2015) |
| "To assess the therapeutic effect of losartan on type 2 diabetes mellitus (DM2) with gas chromatography (GC)-based metabonomics." | 3.74 | [Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics]. ( Gao, P; Lu, X; Shi, XZ; Xu, GW; Yuan, KL, 2007) |
| "The relationship between red blood cell sorbitol content and diabetic complications (cataract, retinopathy, neuropathy, and nephropathy) was examined in 23 non-insulin-dependent diabetic (NIDD) patients." | 3.68 | Studies on clinical markers of diabetes mellitus. 6. Red blood cell sorbitol and diabetic complications. ( Aro, T; Fuda, H; Hatano, M; Hiyoshi, S; Katsu, K; Maruyama, S; Sugiura, M; Taguchi, H, 1990) |
| "Nocturnal hypertension is clinically important for patients with type 2 diabetes (T2D), considering its strong correlation with cardiovascular events." | 2.94 | Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study. ( Aoki, S; Atsumi, T; Cho, KY; Kameda, R; Kawata, S; Kurihara, Y; Miyoshi, H; Nagai, S; Nakamura, A; Nomoto, H; Omori, K; Takeuchi, J, 2020) |
| " The primary objective was to examine the dose-response relationship of licogliflozin treatment in body weight reduction relative to placebo at 12 weeks." | 2.94 | Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity. ( Keefe, D; Sano, M; Tsumiyama, I; Yokote, K, 2020) |
| "Older patients with type 2 diabetes mellitus (T2DM) have an increased risk of bone fracture independent of their bone mineral density (BMD), which is explained mainly by the deteriorated bone quality in T2DM compared to that in non-diabetic adults." | 2.94 | The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT). ( Abiru, N; Chiba, K; Haraguchi, A; Horie, I; Ito, A; Kawakami, A; Kawazoe, Y; Miyamoto, J; Morimoto, S; Osaki, M; Sato, S; Shigeno, R; Tashiro, S; Yamamoto, H, 2020) |
| "Moderately obese Japanese type 2 diabetes patients, treated with luseogliflozin for a year, were observed prospectively and evaluated for body composition changes." | 2.90 | Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study. ( Fukuda, M; Sasaki, T; Sugawara, M, 2019) |
| " Most adverse events were mild in severity." | 2.87 | Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period. ( Fukatsu, A; Imazeki, H; Ochiai, H; Sakai, S; Sasaki, T; Seino, Y, 2018) |
| "A total of 18 Japanese patients with type 2 diabetes were randomized into two groups, in which patients first received luseogliflozin 2." | 2.82 | Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet. ( Nishimura, R; Omiya, H; Sakai, S; Samukawa, Y; Sugio, K; Ubukata, M, 2016) |
| " The safety end points included adverse events (AEs) and laboratory parameters." | 2.82 | Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. ( Fukatsu, A; Haneda, M; Inagaki, N; Kakiuchi, H; Kaku, K; Sakai, S; Samukawa, Y; Sasaki, T; Sato, Y; Seino, Y, 2016) |
| " In safety, the incidence of adverse events was similar between groups, and most of them were mild in severity." | 2.82 | Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials. ( Fukatsu, A; Haneda, M; Inagaki, N; Kakiuchi, H; Kaku, K; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y, 2016) |
| "Although patients with type 2 diabetes often have hepatic impairment, few reports have been published concerning the influence of luseogliflozin on HbA1c and hepatic function in patients with type 2 diabetes accompanied by hepatic impairment." | 2.82 | Luseogliflozin, A Sodium Glucose Co-transporter 2 Inhibitor, Alleviates Hepatic Impairment in Japanese Patients with Type 2 Diabetes. ( Kusunoki, M; Miyata, T; Natsume, Y; Oshida, Y; Sato, D; Suga, T; Tsutsui, H; Tsutsumi, K, 2016) |
| " Seven patients had mild adverse events (AEs); all were resolved." | 2.80 | Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial. ( Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M, 2015) |
| " Safety assessments included adverse events (AEs), clinical laboratory tests, and vital signs." | 2.79 | Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. ( Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M, 2014) |
| "It was developed for the treatment of type 2 diabetes mellitus." | 2.79 | Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial. ( Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y, 2014) |
| " There were no significant differences in the incidences of adverse events among groups." | 2.79 | Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. ( Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y, 2014) |
| "Sorbinil treatment reduced the elevated sorbitol levels in the diabetic patients to normal or slightly below normal, but did not affect the erythrocyte myo-inositol concentration." | 2.65 | myo-Inositol and sorbitol in erythrocytes from diabetic patients before and after sorbinil treatment. ( Lomecky-Janousek, MZ; Popp-Snijders, C; Schouten, JA; van der Veen, EA, 1984) |
| " As these agents have a considerably different glucose-lowering mechanism from those of other anti-diabetic drugs, safe use of this drug class needs to be discussed based on data available from preapproval clinical trials as well as real-world studies." | 2.55 | Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation. ( Hamamoto, Y; Kurose, T; Kuwata, H; Seino, Y; Yabe, D, 2017) |
| "Treatment of type 2 diabetes mellitus (T2DM) continues to present challenges, with many patients failing to achieve glycemic targets." | 2.50 | Clinical implication of SGLT2 inhibitors in type 2 diabetes. ( Chung, SH; Kim, GW, 2014) |
| "She had been suffering from type 2 diabetes mellitus since the age of 50 years." | 1.56 | Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus. ( Fujimori, N; Horiuchi, A; Joshita, S; Kato, N; Kimura, T; Kuribayashi, N; Matsumoto, A; Sano, K; Sugiura, A; Takahashi, Y; Tanaka, E; Tanaka, N; Umemura, T; Yamazaki, T, 2020) |
| " Duration and onset of the pharmacologic effects seemed to be closely correlated with the pharmacokinetic properties of each SGLT2 inhibitor, particularly with respect to high distribution and long retention in the target organ, the kidney." | 1.43 | Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. ( Imamura, M; Kurosaki, E; Tahara, A; Takasu, T; Yokono, M, 2016) |
| " These include the question as to when and to whom early use of SGLT2 inhibitors would be most suitable, as well as instructions on reduction of sulfonylurea dosage during add-on treatment." | 1.42 | Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time? ( Pafili, K; Papanas, N, 2015) |
| "Cataracts were morphologically different and progressed more slowly in T2DC versus T1DC." | 1.40 | Differential proteomic analyses of cataracts from rat models of type 1 and 2 diabetes. ( Chen, S; Ge, J; Guan, L; Leng, F; Liu, P; Su, S; Wang, C; Zhang, L, 2014) |
| "Type 2 diabetes mellitus has reached epidemic proportions; therefore, the search for novel antihyperglycemic drugs is intense." | 1.35 | Novel D-xylose derivatives stimulate muscle glucose uptake by activating AMP-activated protein kinase alpha. ( Alpert, E; Ben Yakir, M; Cerasi, E; Cohen, G; Elgart, A; Gruzman, A; Hoffman, A; Katzhendler, Y; Sandovski, D; Sasson, S; Shamni, O, 2008) |
| "In magnolol-treated GK rats, fasting blood glucose and plasma insulin were significantly decreased, and the pancreatic islets also showed strong insulin antigen positivity." | 1.34 | Effects of magnolol (5,5'-diallyl-2,2'-dihydroxybiphenyl) on diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats. ( Jang, DS; Jung, DH; Kim, CS; Kim, JS; Kim, YS; Lee, YM; Sohn, EJ, 2007) |
| "Diabetic retinopathy was absent in 9/12 subjects (75%), with 3 having mild non-proliferative retinopathy." | 1.30 | Does mitochondrial genome mutation in subjects with maternally inherited diabetes and deafness decrease severity of diabetic retinopathy? ( Boyages, SC; Holmes-Walker, DJ; Mitchell, P, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (5.26) | 18.7374 |
| 1990's | 21 (18.42) | 18.2507 |
| 2000's | 17 (14.91) | 29.6817 |
| 2010's | 45 (39.47) | 24.3611 |
| 2020's | 25 (21.93) | 2.80 |
| Authors | Studies |
|---|---|
| Gruzman, A | 1 |
| Shamni, O | 1 |
| Ben Yakir, M | 1 |
| Sandovski, D | 1 |
| Elgart, A | 1 |
| Alpert, E | 1 |
| Cohen, G | 1 |
| Hoffman, A | 1 |
| Katzhendler, Y | 1 |
| Cerasi, E | 1 |
| Sasson, S | 1 |
| Hashimoto-Kameda, R | 1 |
| Cho, KY | 4 |
| Nomoto, H | 4 |
| Nakamura, A | 4 |
| Omori, K | 4 |
| Nagai, S | 2 |
| Edagawa, S | 1 |
| Kawata, S | 3 |
| Takeuchi, J | 2 |
| Kameda, H | 2 |
| Kurihara, Y | 2 |
| Aoki, S | 4 |
| Atsumi, T | 4 |
| Miyoshi, H | 4 |
| Bando, S | 1 |
| Ichikawa, R | 1 |
| Taguchi, T | 1 |
| Fujimoto, K | 1 |
| Motomiya, T | 1 |
| Taguchi, M | 1 |
| Takano, K | 1 |
| Shichiri, M | 1 |
| Miyatsuka, T | 1 |
| Nakashima, M | 1 |
| Miyoshi, T | 3 |
| Ejiri, K | 3 |
| Kihara, H | 3 |
| Hata, Y | 3 |
| Nagano, T | 3 |
| Takaishi, A | 3 |
| Toda, H | 3 |
| Nanba, S | 2 |
| Nakamura, Y | 3 |
| Akagi, S | 4 |
| Sakuragi, S | 3 |
| Minagawa, T | 3 |
| Kawai, Y | 3 |
| Nishii, N | 3 |
| Fuke, S | 3 |
| Yoshikawa, M | 3 |
| Nakamura, K | 3 |
| Ito, H | 4 |
| Tigchelaar, C | 1 |
| van Zuylen, ML | 1 |
| Hulst, AH | 1 |
| Preckel, B | 1 |
| van Beek, AP | 1 |
| Kema, IP | 1 |
| Hermanides, J | 1 |
| Absalom, AR | 1 |
| Yamauchi, Y | 1 |
| Yokota, T | 1 |
| Takahashi, K | 3 |
| Tsuchida, K | 1 |
| Anzai, T | 1 |
| Tanaka, S | 1 |
| Terauchi, Y | 3 |
| Dupak, R | 1 |
| Hrnkova, J | 1 |
| Simonova, N | 1 |
| Kovac, J | 1 |
| Ivanisova, E | 1 |
| Kalafova, A | 1 |
| Schneidgenova, M | 1 |
| Prnova, MS | 1 |
| Brindza, J | 1 |
| Tokarova, K | 1 |
| Capcarova, M | 1 |
| Namba, S | 1 |
| Chu, KO | 1 |
| Chan, TI | 1 |
| Chan, KP | 1 |
| Yip, YW | 1 |
| Bakthavatsalam, M | 1 |
| Wang, CC | 1 |
| Pang, CP | 1 |
| Brelen, ME | 1 |
| Takihata, M | 1 |
| Kameda, R | 1 |
| de Boer, RA | 1 |
| Núñez, J | 1 |
| Kozlovski, P | 1 |
| Wang, Y | 2 |
| Proot, P | 1 |
| Keefe, D | 2 |
| Yokote, K | 1 |
| Sano, M | 2 |
| Tsumiyama, I | 1 |
| Kohagura, K | 1 |
| Yamasaki, H | 1 |
| Takano, H | 1 |
| Ohya, Y | 1 |
| Seino, Y | 17 |
| Haraguchi, A | 1 |
| Shigeno, R | 1 |
| Horie, I | 1 |
| Morimoto, S | 1 |
| Ito, A | 1 |
| Chiba, K | 1 |
| Kawazoe, Y | 1 |
| Tashiro, S | 1 |
| Miyamoto, J | 1 |
| Sato, S | 1 |
| Yamamoto, H | 1 |
| Osaki, M | 1 |
| Kawakami, A | 1 |
| Abiru, N | 1 |
| Kario, K | 2 |
| Okada, K | 1 |
| Murata, M | 1 |
| Suzuki, D | 1 |
| Yamagiwa, K | 1 |
| Abe, Y | 1 |
| Usui, I | 1 |
| Tsuchiya, N | 1 |
| Iwashita, C | 1 |
| Harada, N | 2 |
| Okawara, Y | 1 |
| Ishibashi, S | 1 |
| Hoshide, S | 2 |
| Patoulias, D | 1 |
| Papadopoulos, C | 1 |
| Katsimardou, A | 1 |
| Toumpourleka, M | 1 |
| Doumas, M | 1 |
| Jeong, SW | 1 |
| He, Y | 1 |
| Pachori, A | 1 |
| Chen, P | 1 |
| Ma, S | 1 |
| Mendonza, AE | 1 |
| Amer, A | 1 |
| Marbury, TC | 1 |
| Hinder, M | 1 |
| Daniels, LJ | 1 |
| Annandale, M | 1 |
| Koutsifeli, P | 1 |
| Li, X | 2 |
| Bussey, CT | 1 |
| van Hout, I | 1 |
| Bunton, RW | 1 |
| Davis, PJ | 1 |
| Coffey, S | 1 |
| Katare, R | 1 |
| Lamberts, RR | 1 |
| Delbridge, LMD | 1 |
| Mellor, KM | 1 |
| Matsumoto, S | 1 |
| Izutsu, T | 1 |
| Kusano, E | 1 |
| Kondo, J | 1 |
| Inoue, H | 1 |
| Antoku, S | 1 |
| Yamasaki, T | 1 |
| Mori, T | 1 |
| Togane, M | 1 |
| Inoue, D | 1 |
| Nishi, H | 1 |
| Inoue, R | 1 |
| Nangaku, M | 1 |
| Jinnouchi, H | 3 |
| Yoshida, A | 1 |
| Tsuyuno, H | 1 |
| Iwamoto, K | 1 |
| Sugiyama, S | 1 |
| Hieshima, K | 1 |
| Kajiwara, K | 1 |
| Kurinami, N | 1 |
| Suzuki, T | 1 |
| Jinnouchi, K | 1 |
| Jinnouchi, T | 1 |
| Tysoe, O | 1 |
| Takenaka, T | 1 |
| Kishimoto, M | 1 |
| Ohta, M | 1 |
| Tomonaga, O | 1 |
| Suzuki, H | 2 |
| Yabe, D | 3 |
| Sasaki, T | 12 |
| Fukatsu, A | 11 |
| Imazeki, H | 3 |
| Ochiai, H | 3 |
| Sakai, S | 15 |
| Shibuya, T | 1 |
| Fushimi, N | 1 |
| Kawai, M | 1 |
| Yoshida, Y | 1 |
| Hachiya, H | 1 |
| Ito, S | 1 |
| Kawai, H | 1 |
| Ohashi, N | 1 |
| Mori, A | 1 |
| Hamamoto, Y | 2 |
| Kuwata, H | 2 |
| Kurose, T | 2 |
| Sugawara, M | 1 |
| Fukuda, M | 1 |
| Samukawa, Y | 14 |
| Haneda, M | 4 |
| Kubo, Y | 1 |
| Sato, Y | 2 |
| Kitao, N | 1 |
| Yamamoto, K | 2 |
| Chen, S | 2 |
| Kimura, T | 3 |
| Obata, A | 2 |
| Shimoda, M | 2 |
| Okauchi, S | 2 |
| Kanda-Kimura, Y | 1 |
| Nogami, Y | 1 |
| Moriuchi, S | 1 |
| Hirukawa, H | 2 |
| Kohara, K | 2 |
| Nakanishi, S | 1 |
| Mune, T | 2 |
| Kaku, K | 5 |
| Kaneto, H | 2 |
| Fujimori, N | 1 |
| Tanaka, N | 1 |
| Sano, K | 1 |
| Horiuchi, A | 1 |
| Kato, N | 1 |
| Takahashi, Y | 2 |
| Kuribayashi, N | 1 |
| Sugiura, A | 1 |
| Yamazaki, T | 1 |
| Joshita, S | 1 |
| Umemura, T | 1 |
| Matsumoto, A | 1 |
| Tanaka, E | 1 |
| Kojima, N | 2 |
| Williams, JM | 1 |
| Takahashi, T | 3 |
| Miyata, N | 2 |
| Roman, RJ | 1 |
| Ferreira, FN | 1 |
| Crispim, D | 1 |
| Canani, LH | 1 |
| Gross, JL | 1 |
| dos Santos, KG | 1 |
| Li, G | 1 |
| Sun, C | 1 |
| Liu, Y | 1 |
| Gang, X | 1 |
| Gao, Y | 1 |
| Li, F | 1 |
| Xiao, X | 1 |
| Wang, G | 1 |
| Ubukata, M | 6 |
| Markham, A | 1 |
| Elkinson, S | 1 |
| Kim, GW | 1 |
| Chung, SH | 1 |
| Su, S | 1 |
| Leng, F | 1 |
| Guan, L | 1 |
| Zhang, L | 1 |
| Ge, J | 1 |
| Wang, C | 1 |
| Liu, P | 1 |
| Pafili, K | 1 |
| Papanas, N | 1 |
| Zanoli, L | 1 |
| Granata, A | 1 |
| Lentini, P | 1 |
| Rastelli, S | 1 |
| Fatuzzo, P | 1 |
| Rapisarda, F | 1 |
| Castellino, P | 1 |
| Nishimura, R | 3 |
| Osonoi, T | 1 |
| Kanada, S | 2 |
| Sugio, K | 2 |
| Omiya, H | 4 |
| Inagaki, N | 3 |
| Hwang, JJ | 1 |
| Johnson, A | 1 |
| Cline, G | 1 |
| Belfort-DeAguiar, R | 1 |
| Snegovskikh, D | 1 |
| Khokhar, B | 1 |
| Han, CS | 1 |
| Sherwin, RS | 1 |
| Giesbertz, P | 1 |
| Padberg, I | 1 |
| Rein, D | 1 |
| Ecker, J | 1 |
| Höfle, AS | 1 |
| Spanier, B | 1 |
| Daniel, H | 1 |
| Aiello, FC | 1 |
| Trovato, FM | 1 |
| Szychlinska, MA | 1 |
| Imbesi, R | 1 |
| Castrogiovanni, P | 1 |
| Loreto, C | 1 |
| Musumeci, G | 1 |
| Kakiuchi, H | 2 |
| Nozaki, K | 2 |
| Watase, H | 2 |
| Shyangdan, DS | 1 |
| Uthman, OA | 1 |
| Waugh, N | 1 |
| Tahara, A | 1 |
| Takasu, T | 1 |
| Yokono, M | 1 |
| Imamura, M | 1 |
| Kurosaki, E | 1 |
| Kusunoki, M | 1 |
| Natsume, Y | 1 |
| Sato, D | 1 |
| Tsutsui, H | 1 |
| Miyata, T | 1 |
| Tsutsumi, K | 1 |
| Suga, T | 1 |
| Oshida, Y | 1 |
| Iwasaki, M | 1 |
| Haraguchi, T | 1 |
| Sumita, K | 1 |
| Yamazato, H | 1 |
| Gugliucci, A | 1 |
| Chukwuma, CI | 1 |
| Islam, MS | 1 |
| Bouchi, R | 1 |
| Terashima, M | 1 |
| Sasahara, Y | 1 |
| Asakawa, M | 1 |
| Fukuda, T | 1 |
| Takeuchi, T | 1 |
| Nakano, Y | 1 |
| Murakami, M | 1 |
| Minami, I | 1 |
| Izumiyama, H | 1 |
| Hashimoto, K | 1 |
| Yoshimoto, T | 1 |
| Ogawa, Y | 1 |
| Hu, J | 1 |
| Zhang, R | 1 |
| Sun, X | 1 |
| Zhang, Q | 1 |
| Guan, X | 1 |
| Chen, J | 1 |
| Zhu, Q | 1 |
| Li, S | 1 |
| Yuan, KL | 1 |
| Shi, XZ | 1 |
| Lu, X | 1 |
| Gao, P | 1 |
| Xu, GW | 1 |
| Takizawa, M | 1 |
| Suzuki, K | 1 |
| Matsubayashi, T | 1 |
| Kikuyama, M | 1 |
| Katsuta, H | 1 |
| Mitsuhashi, J | 1 |
| Nishida, S | 1 |
| Yamaguchi, S | 1 |
| Yoshimoto, K | 1 |
| Itagaki, E | 1 |
| Ishida, H | 1 |
| Kakinuma, H | 1 |
| Oi, T | 1 |
| Hashimoto-Tsuchiya, Y | 1 |
| Arai, M | 1 |
| Kawakita, Y | 1 |
| Fukasawa, Y | 1 |
| Iida, I | 1 |
| Hagima, N | 1 |
| Takeuchi, H | 1 |
| Chino, Y | 1 |
| Asami, J | 1 |
| Okumura-Kitajima, L | 1 |
| Io, F | 1 |
| Yamamoto, D | 1 |
| Uchida, S | 1 |
| Morenkova, SA | 1 |
| Kwang-Hyok, S | 1 |
| Ui-Nam, P | 1 |
| Sarkar, C | 1 |
| Bhadra, R | 1 |
| Regenold, WT | 1 |
| Hisley, KC | 1 |
| Obuchowski, A | 1 |
| Lefkowitz, DM | 1 |
| Marano, C | 1 |
| Hauser, P | 1 |
| Yono, M | 1 |
| Latifpour, J | 1 |
| Yoshida, M | 1 |
| Ueda, S | 1 |
| Nayak, B | 1 |
| Xie, P | 1 |
| Yang, Q | 1 |
| Sun, L | 1 |
| Wada, J | 1 |
| Thakur, A | 1 |
| Danesh, FR | 1 |
| Chugh, SS | 1 |
| Kanwar, YS | 1 |
| Sohn, EJ | 1 |
| Kim, CS | 1 |
| Kim, YS | 1 |
| Jung, DH | 1 |
| Jang, DS | 1 |
| Lee, YM | 1 |
| Kim, JS | 1 |
| Lange, AJ | 1 |
| Shin, JS | 1 |
| Torres, TP | 1 |
| Catlin, RL | 1 |
| Donahue, EP | 1 |
| Shiota, M | 1 |
| Perkins, BA | 1 |
| Bril, V | 1 |
| Reddy, GB | 1 |
| Satyanarayana, A | 1 |
| Balakrishna, N | 1 |
| Ayyagari, R | 1 |
| Padma, M | 1 |
| Viswanath, K | 1 |
| Petrash, JM | 1 |
| Varma, SD | 1 |
| Richards, RD | 1 |
| Popp-Snijders, C | 1 |
| Lomecky-Janousek, MZ | 1 |
| Schouten, JA | 1 |
| van der Veen, EA | 1 |
| Ward, JD | 1 |
| Dayhaw-Barker, P | 1 |
| Vernia, P | 1 |
| Frandina, C | 1 |
| Bilotta, T | 1 |
| Ricciardi, MR | 1 |
| Villotti, G | 1 |
| Fallucca, F | 1 |
| Wang, H | 1 |
| Zhang, ZB | 1 |
| Wen, RR | 1 |
| Zhang, JQ | 1 |
| Mao, XM | 1 |
| Zhou, YP | 1 |
| Hirano, F | 1 |
| Tanaka, H | 1 |
| Okamoto, K | 1 |
| Makino, Y | 1 |
| Inaba, M | 1 |
| Nomura, Y | 1 |
| Fukawa, E | 1 |
| Miura, T | 1 |
| Tani, T | 1 |
| Makino, I | 1 |
| Ciuchi, E | 2 |
| Odetti, P | 2 |
| Prando, R | 2 |
| Anaja, HP | 1 |
| Ito, T | 1 |
| Nishimura, C | 2 |
| Saito, T | 1 |
| Omori, Y | 1 |
| Hotta, N | 2 |
| Nakamura, J | 2 |
| Sakakibara, F | 2 |
| Hamada, Y | 2 |
| Hara, T | 1 |
| Mori, K | 1 |
| Nakashima, E | 1 |
| Sasaki, H | 1 |
| Kasama, N | 1 |
| Inukai, S | 1 |
| Koh, N | 2 |
| Hayashi, R | 1 |
| Hayakawa, N | 1 |
| Makino, M | 1 |
| Nagata, M | 1 |
| Kakizawa, H | 1 |
| Uchimura, K | 1 |
| Hamada, M | 1 |
| Aono, T | 1 |
| Fujita, T | 1 |
| Shinohara, R | 1 |
| Nagasaka, A | 1 |
| Itoh, M | 1 |
| Tanimoto, T | 2 |
| Holmes-Walker, DJ | 1 |
| Mitchell, P | 1 |
| Boyages, SC | 1 |
| Toyoda, Y | 1 |
| Ito, Y | 1 |
| Tanigawa, K | 1 |
| Miwa, I | 1 |
| Yoshii, H | 1 |
| Uchino, H | 1 |
| Ohmura, C | 1 |
| Watanabe, K | 1 |
| Tanaka, Y | 1 |
| Kawamori, R | 1 |
| Kubo, E | 1 |
| Maekawa, K | 1 |
| Fujisawa, S | 1 |
| Akagi, Y | 1 |
| Zumbé, A | 1 |
| Brinkworth, RA | 1 |
| Schaffer, SW | 1 |
| Malaisse, WJ | 1 |
| Hasegawa, G | 1 |
| Tsutsumi, Y | 1 |
| Sawada, M | 1 |
| Setoguchi, J | 1 |
| Nakamura, N | 1 |
| Nakano, K | 1 |
| Kondo, M | 1 |
| Kanatsuna, T | 1 |
| Kuzuya, T | 1 |
| Hatano, M | 1 |
| Katsu, K | 1 |
| Fuda, H | 1 |
| Taguchi, H | 1 |
| Aro, T | 1 |
| Hiyoshi, S | 1 |
| Sugiura, M | 1 |
| Maruyama, S | 1 |
| Loy, A | 1 |
| Lurie, KG | 1 |
| Ghosh, A | 1 |
| Wilson, JM | 1 |
| MacGregor, LC | 1 |
| Matschinsky, FM | 1 |
| Aida, K | 1 |
| Tawata, M | 1 |
| Shindo, H | 1 |
| Onaya, T | 1 |
| Barr, CC | 1 |
| Airey, CM | 1 |
| Price, DE | 1 |
| Kemp, JV | 1 |
| Perkins, CM | 1 |
| Wales, JK | 1 |
| Nakayama, H | 1 |
| Taneda, S | 1 |
| Komori, K | 1 |
| Kuroda, Y | 1 |
| Misawa, K | 1 |
| Tsushima, S | 1 |
| Nakagawa, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 12 Weeks Treatment With 4 Doses of LIK066 Compared to Placebo in Japanese Patients With Obesity Disease[NCT03320941] | Phase 2 | 126 participants (Actual) | Interventional | 2017-12-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The dose-response relationship of LIK066 as measured by percent change from baseline in body weight relative to placebo after 12 weeks of treatment. (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percent Change (Number) |
|---|---|
| LIK066 2.5mg qd | -1.86 |
| LIK066 10mg qd | -2.84 |
| LIK066 25 mg qd | -3.41 |
| LIK066 50 mg qd | -3.80 |
| Placebo | 0.11 |
Plasma trough concentrations of LIK066 were measured at Week 12 after daily administrations of LIK066 (2.5, 10, 25 and 50 mg). (NCT03320941)
Timeframe: Week 12
| Intervention | ng/mL (Mean) |
|---|---|
| LIK066 2.5mg qd | 1.63 |
| LIK066 10mg qd | 4.17 |
| LIK066 25 mg qd | 12.8 |
| LIK066 50 mg qd | 26.4 |
After the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, DBP will be measured three times using the automatic BP monitor and an appropriate size cuff. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | mmHg (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -3.54 | -4.40 | -2.45 |
| LIK066 2.5mg qd | -3.72 | -3.32 | -4.00 |
| LIK066 25 mg qd | -4.36 | -2.46 | -5.98 |
| LIK066 50 mg qd | -5.23 | -4.25 | -5.92 |
| Placebo | -3.12 | -4.31 | -1.93 |
FPG will be measured from a blood sample obtained after an overnight fast (at least 8h after last evening food intake) at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | mmol/L (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -0.665 | -0.126 | -1.111 |
| LIK066 2.5mg qd | -0.334 | 0.002 | -0.606 |
| LIK066 25 mg qd | -0.747 | -0.262 | -1.145 |
| LIK066 50 mg qd | -0.986 | -0.472 | -1.377 |
| Placebo | -0.160 | -0.217 | -0.079 |
After the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, SBP will be measured three times using the automatic BP monitor and an appropriate size cuff. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | mmHg (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -5.12 | -7.10 | -2.96 |
| LIK066 2.5mg qd | -4.90 | -5.79 | -4.16 |
| LIK066 25 mg qd | -6.36 | -3.58 | -8.63 |
| LIK066 50 mg qd | -6.94 | -4.17 | -9.00 |
| Placebo | -5.36 | -7.09 | -3.77 |
Waist circumference will be measured to the nearest 0.1 cm in a standing position, at the end of a normal expiration, using a tape at the level of umbilicus. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | cm (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -2.63 | -4.49 | -1.39 |
| LIK066 2.5mg qd | -2.47 | -2.78 | -2.22 |
| LIK066 25 mg qd | -2.65 | -2.08 | -2.90 |
| LIK066 50 mg qd | -3.11 | -2.23 | -3.88 |
| Placebo | -1.37 | -0.41 | -2.19 |
Uric acid will be measured from a blood sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | μmol/L (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -55.2 | -74.0 | -39.7 |
| LIK066 2.5mg qd | -52.6 | -74.9 | -34.1 |
| LIK066 25 mg qd | -58.4 | -69.1 | -48.4 |
| LIK066 50 mg qd | -62.0 | -72.9 | -51.6 |
| Placebo | 12.4 | 12.0 | 13.4 |
Urine albumin will be measured from urine sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | x 10^4 mmol/L (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | 0.008 | 2.030 | -1.051 |
| LIK066 2.5mg qd | -1.838 | -1.941 | -3.899 |
| LIK066 25 mg qd | -3.902 | -2.456 | -3.605 |
| LIK066 50 mg qd | -3.099 | -3.406 | -2.165 |
| Placebo | -1.282 | -3.611 | -0.174 |
Urine albumin to creatinine ratio will be measured from urine sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | mg/mmol (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -0.848 | 0.487 | -1.863 |
| LIK066 2.5mg qd | -0.849 | -0.553 | -1.234 |
| LIK066 25 mg qd | -2.552 | -0.771 | -4.005 |
| LIK066 50 mg qd | -1.878 | -1.018 | -2.631 |
| Placebo | -1.504 | -1.122 | -1.839 |
High sensitivity CRP will be measured from a blood sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | 69.004 | 6.593 | 113.169 |
| LIK066 2.5mg qd | -48.448 | 16.582 | -89.337 |
| LIK066 25 mg qd | -24.207 | -36.745 | -18.143 |
| LIK066 50 mg qd | -55.536 | -43.562 | -71.025 |
| Placebo | -93.268 | -6.298 | -174.159 |
SFA by CT scan will be measured at visits and evaluated centrally. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -4.454 | -5.962 | -3.646 |
| LIK066 2.5mg qd | -6.562 | -7.745 | -5.457 |
| LIK066 25 mg qd | -7.983 | -7.234 | -8.415 |
| LIK066 50 mg qd | -5.745 | -2.127 | -8.481 |
| Placebo | -3.477 | -4.328 | -2.821 |
VFA by CT scan will be measured at visits and evaluated centrally. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percent (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -5.832 | -6.438 | -5.934 |
| LIK066 2.5mg qd | -4.139 | -1.532 | -6.461 |
| LIK066 25 mg qd | -9.185 | -5.977 | -12.916 |
| LIK066 50 mg qd | -11.352 | -7.333 | -14.728 |
| Placebo | -3.949 | -0.390 | -7.137 |
Fasting lipid profile (HDL), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -2.461 | 0.329 | -4.696 |
| LIK066 2.5mg qd | 1.499 | -0.519 | 2.886 |
| LIK066 25 mg qd | -5.253 | -3.279 | -6.993 |
| LIK066 50 mg qd | 0.112 | -0.147 | 0.235 |
| Placebo | -3.454 | -4.329 | -2.677 |
Fasting lipid profile (LDL), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -2.363 | -4.473 | -1.562 |
| LIK066 2.5mg qd | 0.757 | -3.065 | 3.727 |
| LIK066 25 mg qd | 0.037 | 2.579 | -1.295 |
| LIK066 50 mg qd | 4.726 | 2.128 | 6.803 |
| Placebo | -0.552 | -3.994 | 2.942 |
Fasting lipid profile (total cholesterol), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -2.983 | -6.017 | -1.367 |
| LIK066 2.5mg qd | -1.290 | -3.055 | 0.158 |
| LIK066 25 mg qd | 0.884 | 4.273 | -1.646 |
| LIK066 50 mg qd | 0.302 | -1.734 | 1.817 |
| Placebo | -2.244 | -3.559 | -0.671 |
Fasting lipid profile (Triglycerides (TG)), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | 11.057 | -1.986 | 23.108 |
| LIK066 2.5mg qd | 1.840 | -1.153 | 1.016 |
| LIK066 25 mg qd | 43.928 | 52.284 | 34.747 |
| LIK066 50 mg qd | 5.307 | 14.061 | -0.057 |
| Placebo | 17.401 | 20.962 | 13.806 |
HbA1c will be measured from a blood sample obtained and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Overall Study | Dysglycemic | T2DM | |
| LIK066 10mg qd | -0.355 | -0.184 | -0.491 |
| LIK066 2.5mg qd | -0.285 | -0.139 | -0.405 |
| LIK066 25 mg qd | -0.366 | -0.196 | -0.502 |
| LIK066 50 mg qd | -0.418 | -0.163 | -0.618 |
| Placebo | -0.079 | -0.050 | -0.093 |
The dose-response relationship for weight loss in dysglycemic participants and participants with T2DM. Percentage change from baseline in body weight at Week 12. (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | percentage change (Number) | |
|---|---|---|
| Dysglycemic | T2DM | |
| LIK066 10mg qd | -2.95 | -2.66 |
| LIK066 2.5mg qd | -1.90 | -1.64 |
| LIK066 25 mg qd | -3.29 | -3.42 |
| LIK066 50 mg qd | -3.47 | -4.23 |
| Placebo | 0.00 | 0.10 |
The responder rates according to percentage decrease in body weight either ≥ 3%, ≥ 5% or ≥ 10%, from baseline at Week 12, for the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 No Statistical Analysis for >=5% and >=10% was not calculated due to division by zero (NCT03320941)
Timeframe: Baseline, Week 12
| Intervention | Percentage of Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| >= 3% | >= 5% | >= 10% | >= 3% (Dysglycemic) | >= 5% (Dysglycemic) | >= 10% (Dysglycemic) | >= 3% (T2DM) | >= 5% (T2DM) | >= 10% (T2DM) | |
| LIK066 10mg qd | 55.6 | 27.8 | 0.0 | 75.0 | 62.5 | 0.0 | 40.0 | 0.00 | 0.00 |
| LIK066 2.5mg qd | 15.8 | 5.3 | 0.0 | 12.5 | 0.0 | 0.0 | 18.2 | 9.1 | 0.00 |
| LIK066 25 mg qd | 50.0 | 17.9 | 0.0 | 38.5 | 23.1 | 0.0 | 60.0 | 13.3 | 0.00 |
| LIK066 50 mg qd | 56.7 | 26.7 | 3.3 | 46.2 | 23.1 | 0.0 | 64.7 | 29.4 | 5.9 |
| Placebo | 7.1 | 0.0 | 0.0 | 7.7 | 0.0 | 0.0 | 6.7 | 0.00 | 0.00 |
12 reviews available for sorbitol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.
Topics: Administration, Oral; Aged; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2017 |
Clinical implication of SGLT2 inhibitors in type 2 diabetes.
Topics: Administration, Oral; Benzhydryl Compounds; Canagliflozin; Clinical Trials, Phase III as Topic; Diab | 2014 |
Luseogliflozin for the treatment of type 2 diabetes.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Half- | 2014 |
Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease.
Topics: Animals; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rat | 2015 |
Molecular Links Between Diabetes and Osteoarthritis: The Role of Physical Activity.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diglycerides; Disease Progression; Exercise; G | 2017 |
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
Topics: Bayes Theorem; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug | 2016 |
Formation of Fructose-Mediated Advanced Glycation End Products and Their Roles in Metabolic and Inflammatory Diseases.
Topics: Adenosine Triphosphate; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Fructose; Glycat | 2017 |
Emerging therapies for diabetic neuropathy: a clinical overview.
Topics: Aldehyde Reductase; Autonomic Nervous System Diseases; Blood Glucose; Diabetes Mellitus, Type 2; Dia | 2005 |
Mechanisms of pathogenesis in diabetes mellitus.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Histocompatibilit | 1995 |
Cardiomyopathy associated with noninsulin-dependent diabetes.
Topics: Animals; Animals, Newborn; Calcium; Cardiomyopathies; Carrier Proteins; Diabetes Mellitus, Experimen | 1991 |
The anomeric malaise: a manifestation of B-cell glucotoxicity.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glycogen; Glycosylatio | 1991 |
Diabetic retinopathy.
Topics: Adult; Aldehyde Reductase; Aneurysm; Capillaries; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type | 1986 |
37 trials available for sorbitol and Diabetes Mellitus, Type 2
65 other studies available for sorbitol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Novel D-xylose derivatives stimulate muscle glucose uptake by activating AMP-activated protein kinase alpha.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Drug Design; Enzyme Activation; G | 2008 |
Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hypogl | 2022 |
Elevated cerebrospinal fluid glucose levels and diabetes mellitus are associated with activation of the neurotoxic polyol pathway.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Fructose; Glucose; Humans; Hyperglycemia; Polymers; | 2022 |
Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function.
Topics: Animals; Diabetes Mellitus, Type 2; Insulin-Secreting Cells; Mice; Mice, Inbred Strains; Mitochondri | 2022 |
The consumption of sea buckthorn (Hippophae rhamnoides L.) effectively alleviates type 2 diabetes symptoms in spontaneous diabetic rats.
Topics: Animals; Antioxidants; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Frui | 2022 |
Untargeted metabolomic analysis of aqueous humor in diabetic macular edema.
Topics: Antioxidants; Aqueous Humor; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fatty Acids; Glucose; | 2022 |
Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, | 2020 |
Sodium-glucose co-transporter-2 inhibitors and arterial stiffness: Class effect or drug effect?
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Hypertension; Pharmaceutical Preparations; Sodium; Sodiu | 2020 |
Randomized, "head-to-head" studies comparing different SGLT2 inhibitors are definitely needed.
Topics: Diabetes Mellitus, Type 2; Humans; Hypertension; Hypoglycemic Agents; Sodium-Glucose Transporter 2 I | 2020 |
Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming.
Topics: Anhydrides; Diabetes Mellitus, Type 2; End Stage Liver Disease; Fibroblast Growth Factors; Humans; N | 2020 |
Elevated myocardial fructose and sorbitol levels are associated with diastolic dysfunction in diabetic patients, and cardiomyocyte lipid inclusions in vitro.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fructokinases; F | 2021 |
Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiologists; Cardiovascular System; | 2021 |
Changes in urinary glucose concentration and body weight in patients treated with the selective SGLT2 inhibitor luseogliflozin.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Body Weight; Diabetes Mellitus, Type 2; Glucose; Human | 2021 |
Licogliflozin effective in PCOS treatment.
Topics: Anhydrides; Diabetes Mellitus, Type 2; Female; Humans; Polycystic Ovary Syndrome; Sodium-Glucose Tra | 2021 |
Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy.
Topics: Albuminuria; Biomarkers; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Canag | 2017 |
Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages.
Topics: Age Factors; Animals; Cyclin D2; Diabetes Mellitus, Type 2; Disease Models, Animal; Homeodomain Prot | 2018 |
Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical trials.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Rate; Humans | 2018 |
Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β-cells in db/db mice: The earlier and longer, the better.
Topics: Animals; Cells, Cultured; Cytoprotection; Diabetes Complications; Diabetes Mellitus, Experimental; D | 2018 |
Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase I | 2020 |
Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabe | 2013 |
Association study of sorbitol dehydrogenase -888G>C polymorphism with type 2 diabetic retinopathy in Caucasian-Brazilians.
Topics: Adult; Aldehyde Reductase; Brazil; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Retinop | 2013 |
A clinical and neuropathological study of Chinese patients with diabetic peripheral neuropathy.
Topics: Adult; Biopsy; Blood Glucose; Case-Control Studies; China; Diabetes Mellitus, Type 2; Diabetic Neuro | 2014 |
Luseogliflozin: first global approval.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Drug Approval; Drug Therapy, Combination; | 2014 |
Differential proteomic analyses of cataracts from rat models of type 1 and 2 diabetes.
Topics: Adenosine Triphosphate; Aldehyde Reductase; Analysis of Variance; Animals; Cataract; Diabetes Mellit | 2014 |
Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sodium-Glucose T | 2015 |
Fructose levels are markedly elevated in cerebrospinal fluid compared to plasma in pregnant women.
Topics: Adult; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Fructose | 2015 |
Metabolite profiling in plasma and tissues of ob/ob and db/db mice identifies novel markers of obesity and type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Fatty Acids; Gas Chromato | 2015 |
Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice.
Topics: Animals; Apoptosis; Cell Proliferation; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; | 2016 |
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Delayed-Action Preparations; Diabetes M | 2016 |
SGLT2 inhibitor (Luseogliflozin): a new mechanism for treating type 2 diabetes mellitus and therapeutic potential to prevent the progression of diabetic complications.
Topics: Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Hu | 2016 |
Sorbitol increases muscle glucose uptake ex vivo and inhibits intestinal glucose absorption ex vivo and in normal and type 2 diabetic rats.
Topics: Absorption, Physiological; Animals; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Gastric Emptyi | 2017 |
Urocortin ameliorates diabetic nephropathy in obese db/db mice.
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cell Line; Connective Tissue Growth Factor | 2008 |
[Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics].
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Biomarkers; Chromatography, Gas; Creatinine; Deoxyguanosin | 2007 |
Increased bone resorption may play a crucial role in the occurrence of osteopenia in patients with type 2 diabetes: Possible involvement of accelerated polyol pathway in its pathogenesis.
Topics: Acid Phosphatase; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Diabetes Mellitus, Type 2 | 2008 |
(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.
Topics: Animals; Biological Availability; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; CHO Cell | 2010 |
[Comparative analysis of dependence of saliva sorbitol and fructosamine levels on blood glucose level in patients with diabetes].
Topics: Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female | 2004 |
A sensitive assay of red blood cell sorbitol level by high performance liquid chromatography: potential for diagnostic evaluation of diabetes.
Topics: Adult; Calibration; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Erythrocytes; H | 2005 |
Relationship of white matter hyperintensities to cerebrospinal fluid glucose polyol pathway metabolites-a pilot study in treatment-resistant affective disorder patients.
Topics: Adult; Aged; Bipolar Disorder; Blood Glucose; Brain; Brain Diseases, Metabolic; Cyclohexanols; Depre | 2005 |
Age-related alterations in the biochemical and functional properties of the bladder in type 2 diabetic GK rats.
Topics: Acetylcholine; Adenosine Triphosphate; Aging; Animals; Body Weight; Carbachol; Diabetes Complication | 2005 |
Modulation of renal-specific oxidoreductase/myo-inositol oxygenase by high-glucose ambience.
Topics: Animals; Blood Glucose; Blotting, Northern; Blotting, Western; Cells, Cultured; Diabetes Mellitus, T | 2005 |
Effects of magnolol (5,5'-diallyl-2,2'-dihydroxybiphenyl) on diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats.
Topics: Animals; Biphenyl Compounds; Blood Glucose; Collagen Type IV; Creatinine; Diabetes Mellitus, Experim | 2007 |
For the ZDF rat, "Breaking up is hard to do": dissociation of the GK:GKRP complex.
Topics: Adaptor Proteins, Signal Transducing; Animals; Blood Glucose; Carrier Proteins; Diabetes Mellitus, T | 2007 |
A defect in glucose-induced dissociation of glucokinase from the regulatory protein in Zucker diabetic fatty rats in the early stage of diabetes.
Topics: Animals; Blood Glucose; Carrier Proteins; Diabetes Mellitus, Type 2; Fasting; Glucagon; Glucokinase; | 2007 |
Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy.
Topics: Aldehyde Reductase; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Retinop | 2008 |
Etiology of cataracts in diabetics.
Topics: Adolescent; Adult; Aldehyde Reductase; Animals; Blood Glucose; Cataract; Child; Child, Preschool; Di | 1984 |
[The problem of the complications of diabetes].
Topics: Blood Glucose; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellit | 1984 |
Sorbitol malabsorption and nonspecific abdominal symptoms in type II diabetes.
Topics: Abdomen; Aged; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Malabsor | 1995 |
[Effects of silybin on red blood cell sorbitol and nerve conduction velocity in diabetic patients].
Topics: Diabetes Mellitus, Type 2; Erythrocytes; Female; Humans; Male; Middle Aged; Neural Conduction; Silym | 1993 |
Natural course of diabetic peripheral neuropathy in spontaneous-onset diabetic Chinese hamsters.
Topics: Aging; Animals; Cricetinae; Cricetulus; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Electrophy | 1995 |
Relationship between glutathione and sorbitol concentrations in erythrocytes from diabetic patients.
Topics: Diabetes Mellitus, Type 2; Erythrocytes; Glutathione; Humans; Middle Aged; Sorbitol | 1996 |
The effect of acute glutathione treatment on sorbitol level in erythrocytes from diabetic patients.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Erythrocytes; Glutathione; Humans; Middle Aged; Sor | 1997 |
Diagnostic performance of red cell sorbitol assay in a Nigerian teaching hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Child; Confidence Intervals; Diabetes Mel | 1997 |
The level of erythrocyte aldose reductase: a risk factor for diabetic neuropathy?
Topics: Adult; Age Factors; Aged; Aldehyde Reductase; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neu | 1997 |
Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant.
Topics: 2,3-Diphosphoglycerate; Aldehyde Reductase; Animals; Anticoagulants; Blood Glucose; Body Weight; Cil | 1997 |
Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
Topics: Adolescent; Adult; Aged; Aldehyde Reductase; Blood Glucose; Child; Diabetes Mellitus, Type 1; Diabet | 1998 |
Influence of interindividual variability of aldose reductase protein content on polyol-pathway metabolites and redox state in erythrocytes in diabetic patients.
Topics: Aldehyde Reductase; Antibodies; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorben | 1998 |
Does mitochondrial genome mutation in subjects with maternally inherited diabetes and deafness decrease severity of diabetic retinopathy?
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Blood Glucose; Deafness; Diabetes Mellitus, Type 2; Di | 1998 |
Impairment of glucokinase translocation in cultured hepatocytes from OLETF and GK rats, animal models of type 2 diabetes.
Topics: Animals; Cell Nucleus; Cells, Cultured; Cytoplasm; Diabetes Mellitus, Type 2; Disease Models, Animal | 2000 |
Clinical usefulness of measuring urinary polyol excretion by gas-chromatography/mass-spectrometry in type 2 diabetes to assess polyol pathway activity.
Topics: Adult; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retino | 2001 |
Biochemical and morphological changes during development of sugar cataract in Otsuka Long-Evans Tokushima fatty (OLETF) rat.
Topics: Aldehyde Reductase; Animals; Cataract; Diabetes Mellitus, Type 2; Disease Models, Animal; L-Iditol 2 | 2001 |
[Etiology of chronic complications diabetes mellitus and the plan for their management].
Topics: Arteriosclerosis; Blood Glucose; Collagen; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycosylati | 1991 |
Studies on clinical markers of diabetes mellitus. 6. Red blood cell sorbitol and diabetic complications.
Topics: Biomarkers; Cataract; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; Eryth | 1990 |
Diabetes and the myo-inositol paradox.
Topics: Animals; Aqueous Humor; Blood Glucose; Cornea; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 1990 |
Clinical significance of erythrocyte sorbitol-blood glucose ratios in type II diabetes mellitus.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; E | 1990 |
Antibodies to nonenzymatically glucosylated albumin in the human serum.
Topics: Adult; Antigens; Autoantibodies; Binding, Competitive; Diabetes Mellitus, Type 1; Diabetes Mellitus, | 1985 |